Drugs / MMF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02661035 | Mar 2017 → Apr 2023 | Burkitt lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myeloid leukemia +8 | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02661035 ↗ |
| Route | Intravenous | “3 gram/day IV/PO for patients who are ≥ 40 kg” NCT02661035 ↗ |
| Route | Oral | “3 gram/day IV/PO for patients who are ≥ 40 kg” NCT02661035 ↗ |